Spinal Muscular Atrophy Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with infantile or juvenile spinal muscular atrophy (SMA), confirmed by genetic testing
- You are currently being treated with a medication that helps the body produce SMN protein (such as nusinersen, risdiplam, or onasemnogene abeparvovec)
- You are between 0 and 15 years old (inclusive)
- A parent or legal guardian has given written consent, and the child has also given their agreement where appropriate
- You are covered by a health insurance plan (this requirement applies to participants joining the trial in France only)
Who may not be able to join:
- You have another health condition that is not related to SMA and could significantly affect how the trial assessments are carried out
- You have another neurological (brain or nerve) condition in addition to SMA
- You are currently pregnant or breastfeeding (a pregnancy test will be done at the start of the trial to check this)
Please note: If you have a reason why you cannot have an MRI scan — such as a metal implant in your body, claustrophobia, or another reason identified by the medical team — you may still be able to take part in the trial, but the MRI part of the study would be skipped for you.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 04.72.12.95.04
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Markers of disease progression and description of different phenotypes, at : muscular and functional; Markers of disease progression and description of different phenotypes, at : muscular and functional; Markers of disease progression and description of different phenotypes, at : muscular and functional; Markers of disease progression and description of different phenotypes, at : muscular and functional; Markers of disease progression and description of different phenotypes, at : muscular and functional; Markers of disease progression and description of different phenotypes, at : Fatigue; Mark...
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.